Further Information
F13A1, coagulation factor XIII, A1 polypeptide, RP11-232H4.1, F13A, Coagulation factor XIII A chain, Coagulation factor XIII, A polypeptide, TGase, bA525O21.1 (coagulation factor XIII, A1 polypeptide), coagulation factor XIII A1 subunit, factor XIIIa
ELISA: 2-4 ug/ml; order the BSA-free formulation for coating
Immunofluorescence: 1-2 ug/ml
Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Western blot: 0.5-1 ug/ml
Immunohistochemistry (FFPE): 1-2 ug/ml for 30 min at RT
Prediluted IHC only format: incubate for 30 min at RT (1)
Titering of the Factor XIIIa antibody may be required for optimal performance.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Factor XIIIa has been identified in platelets, megakaryocytes, and fibroblast-like mesenchymal or histiocytic cells in the placenta, uterus, and prostate, monocytes and macrophages and dermal dendritic cells. Anti-Factor XIIIa has been found to be useful in differentiating between dermatofibroma (almost all cases are positive), dermatofibrosarcoma protuberans (-/+) and desmoplastic malignant melanoma (-). Anti-Factor XIIIa positivity is also seen in capillary hemagioblastoma, hemangioendothelioma, hemangiopericytoma, xanthogranuloma, xanthoma, hepatocellular carcinoma, glomus tumor, and meningioma.
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
0.2 mg/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
A human partial recombinant protein corresponding to amino acids 46-181 was used as the immunogen for the Factor XIIIa antibody.
2162
coagulation factor XIII, A1 polypeptide
F13A1
Homo sapiens
Liquid
Protein G affinity chromatography
Cancer
P00488
Optimal dilutions for each application to be determined by the researcher